Real-world use of insulin degludec/liraglutide (IDegLira) significantly improves glycaemic control in patients with Type 2 diabetes

被引：0
|
作者：
Feher, M. [1 ]
Price, H. [2 ]
Schultes, B. [3 ]
Prager, R. [4 ]
Phan, T. M. [5 ]
Thorsted, B. L. [6 ]
Bluher, M. [7 ]
机构：
[1] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[2] Southern Hlth NHS Fdn Trust, Bournemouth, Dorset, England
[3] ESwiss Med & Surg Ctr, Internal Med, St Gallen, Switzerland
[4] Hietzing Hosp, Dept Metab Disorders & Nephrol, Vienna, Austria
[5] Novo Nordisk Reg Europe Pharmaceut AS, Copenhagen, Denmark
[6] Novo Nordisk AS, Global Market Access, Soborg, Denmark
[7] Univ Leipzig, Dept Med, Leipzig, Germany
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P391
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [1] Switching to insulin degludec (IDeg) improves glycaemic control in patients with Type 2 diabetes in a real-world setting
    Feher, M.
    Tentolouris, N.
    Knudsen, S.
    Lapolla, A.
    Prager, R.
    Phan, T. M.
    Wolden, M. L.
    Schultes, B.
    DIABETIC MEDICINE, 2018, 35 : 203 - 203
  • [2] Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
    Gough, Stephen C. L.
    Jain, Rajeev
    Woo, Vincent C.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) : 7 - 19
  • [3] Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin
    Kumar, S.
    Aroda, V.
    Bailey, T.
    Cariou, B.
    Leiter, L.
    Raskin, P.
    Zacho, J.
    Philis-Tsimikas, A.
    DIABETIC MEDICINE, 2015, 32 : 66 - 66
  • [4] Real-World Use of IDegLira Significantly Improves Glycemic Control in Patients with T2D
    Price, Hermione
    Schultes, Bernd
    Prager, Rudolf
    Tra Mi Phan
    Thorsted, Brian L.
    Bluher, Matthias
    DIABETES, 2017, 66 : A257 - A257
  • [5] Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
    Meneghini, L.
    Doshi, A.
    Gouet, D.
    Vilsboll, T.
    Begtrup, K.
    Orsy, P.
    Ranthe, M. F.
    Lingvay, I.
    DIABETIC MEDICINE, 2020, 37 (02) : 267 - 276
  • [6] Patients with type 2 diabetes on the maximum dose of insulin degludec/liraglutide (IDegLira) achieve glycaemic target: analyses from the DUAL programme
    Meneghini, L.
    Linjawi, S.
    Serusclat, P.
    Vilsboll, T.
    Agner, B. F.
    Hansen, T.
    Leiter, L. A.
    DIABETOLOGIA, 2018, 61 : S413 - S413
  • [7] In patients with Type 2 diabetes, treatment with IDegLira, a combination of insulin degludec and liraglutide, improves both preprandial and postprandial plasma glucose
    Viljoen, A.
    King, A.
    Philis-Tsimikas, A.
    Langbakke, I. H.
    Kvist, K.
    Vilsboll, T.
    DIABETIC MEDICINE, 2015, 32 : 74 - 74
  • [8] INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE
    Al Awadi, F.
    Aly, H.
    Bashier, A.
    Benavente, J. Medina
    Dhanwal, D. Kumar
    Jallo, M.
    Singhal, S.
    Abusnana, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [9] IDegLira, a combination of insulin degludec and liraglutide, improves both pre- and postprandial plasma glucose in patients with type 2 diabetes
    King, A.
    Philis-Tsimikas, A.
    Langbakke, I. H.
    Kvist, K.
    Vilsboll, T.
    DIABETOLOGIA, 2014, 57 : S108 - S109
  • [10] IDegLira, a combination of insulin degludec and liraglutide, enables patients with type 2 diabetes to reach target glycaemic control faster than its individual components alone
    Vilsboll, T.
    Vora, J.
    Jarlov, H.
    Kvist, K.
    Blonde, L.
    DIABETOLOGIA, 2014, 57 : S339 - S339
12345